Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

New Life Pharma LLC

Has New Life Pharma LLC received an FDA warning letter? Yes. FDA issued a warning letter dated April 14, 2026 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
April 14, 2026 (2026-04-14)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Manufacturer / API
Products named
Semaglutide Sterile Multi-Dose VialTirzepatide Sterile Multi-Dose Vial
Violation categories
Unapproved new drugMisbrandingCGMP / insanitary conditions

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

Factual Violation Summary

FDA says the firm manufactured unapproved semaglutide and tirzepatide sterile multi-dose vials without FDA approval, failed to register and list, lacked sterility and CGMP controls, and denied FDA investigators access to manufacturing areas.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Unapproved new drugs
  • Misbranded drugs (failure to register and list)
  • CGMP violations (sterility assurance and quality control)
  • Adulteration (delaying, denying, limiting, or refusing inspection)

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.